Chenxi Su, Jiaqi Wu, Liping Jiang, Tongtong Lv, Wenxi Liu, Jintong Zhang, Yanhua Zhang, Xiaochun Peng, Jie Tan
{"title":"Application of cfDNA methylation in cancer prognostic assessment: Progress and challenges (Review).","authors":"Chenxi Su, Jiaqi Wu, Liping Jiang, Tongtong Lv, Wenxi Liu, Jintong Zhang, Yanhua Zhang, Xiaochun Peng, Jie Tan","doi":"10.3892/ijo.2025.5804","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer prognostic assessment constitutes an essential component of cancer treatment and management. It encompasses the prediction of patients' disease progression, treatment effect and survival. Circulating free DNA (cfDNA) refers to highly fragmented DNA that exists extracellularly in the human bloodstream. Its methylation status is not only a reliable indicator for the prognosis of cancer, but also a highly accurate predictor of the prognosis of cancer. As an emerging non‑invasive biomarker, cfDNA has demonstrated considerable potential in cancer prognostic assessment in recent years. The present review provided a comprehensive review of the promising applications of cfDNA methylation in cancer prognostic assessment, while also discussing the challenges that must be addressed to fully realize its clinical potential. As technology advances and research deepens, cfDNA methylation is expected to play an increasingly pivotal role in the field of cancer precision medicine.</p>","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 6","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijo.2025.5804","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer prognostic assessment constitutes an essential component of cancer treatment and management. It encompasses the prediction of patients' disease progression, treatment effect and survival. Circulating free DNA (cfDNA) refers to highly fragmented DNA that exists extracellularly in the human bloodstream. Its methylation status is not only a reliable indicator for the prognosis of cancer, but also a highly accurate predictor of the prognosis of cancer. As an emerging non‑invasive biomarker, cfDNA has demonstrated considerable potential in cancer prognostic assessment in recent years. The present review provided a comprehensive review of the promising applications of cfDNA methylation in cancer prognostic assessment, while also discussing the challenges that must be addressed to fully realize its clinical potential. As technology advances and research deepens, cfDNA methylation is expected to play an increasingly pivotal role in the field of cancer precision medicine.
期刊介绍：
The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality.
The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research.
All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
